Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019

  10 January 2020

Three years after the first identification of C. aurisin New York, pan-resistant isolates remain rare. Continued surveillance for C. auris, prudent antifungal use, and susceptibility testing for all C. aurisclinical isolates (especially after patients have been treated with antifungal drugs) are needed.

Further reading: CDC
Author(s): Belinda Ostrowsky, Jane Greenko, Eleanor Adams, Monica Quinn, Brittany O’Brien, Vishnu Chaturvedi, Elizabeth Berkow, Snigdha Vallabhaneni, Kaitlin Forsberg, Sudha Chaturvedi, Emily Lutterloh, Debra Blog
Effective Surveillance  

Registration now open:

International Masterclass AMR 29 SEP delivered digitally: 2 = 1!


  • Science, Health-Economic & Societal impact
  • Global causes and global solutions
  • Bottom-up, interactive approach
  • International Experts involved

Offered online!

Register today >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!